Development of Nanoparticle‐Hydrogel Drug Delivery System for Sustained Release of Anti‐VEGF Peptide in Ocular Neovascularization Treatment
Macromolecular Bioscience · 2026
DOI: 10.1002/mabi.202500263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Macromolecular Bioscience, 2026. Verfasst von Saliha Durak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Nanoparticles, Retinal Neovascularization, Hydrogels. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Scientific and Technological Research Council of Turkey (TUBITAK).
Abstract (Originalsprache)
Vascular Endothelial Growth Factor (VEGF) is a critical factor in pathological neovascularization, making it the primary target for ocular anti‐angiogenic therapies. Anti‐VEGF treatments suffer from requiring frequent intraocular injections for effective treatment due to limited half‐life. This study aimed to utilize a composite nanoparticle‐hydrogel drug delivery system consisting of poly(glycerol sebacate) (PGS) nanoparticles and cross‐linked hyaluronic acid hydrogel to achieve an extended release of anti‐VEGF agent, HRH peptide, with the objective of reducing the frequency of intravitreal injections required for treatment of neovascular diseases. Our findings reveal a promising 42.54% ± 5.99% drug release from HA‐PGS NP@HRH within the first 3 months, indicating potential for sustained drug release applications. Cell viability studies demonstrate biocompatibility with human retinal pigment epithelium (ARPE‐19) cells and reveal anti‐angiogenic effects by binding to VEGF receptors on human umbilical vein endothelial (HUVEC) cells, inhibiting VEGF activity, cell growth (with 55.19% cell viability), and tube formation of HUVECs. In vivo experiments with an oxygen‐induced retinopathy (OIR) model demonstrated a suppression of neovascularization in mice treated with PGS NPs@HRH. Our research strives to contribute to the development of these new‐generation materials, promising improved treatment efficacy and ultimately enhancing the quality of life for patients affected by these challenging conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanotechnology Research and Application Center (SUNUM), Sabanci University, Istanbul, Turkey.
- Faculty of Engineering and Natural Sciences, Molecular Biology, Genetics and Bioengineering Program, Sabanci University, Istanbul, Turkey.
- Faculty of Engineering and Natural Sciences, Materials Science and Nano-Engineering Program, Sabanci University, Istanbul, Turkey.
- Kocaeli University School of Medicine, Department of Ophthalmology, Kocaeli, Turkey.
ORCID-Profile: Sibel Cetinel
Förderung
- Scientific and Technological Research Council of Turkey (TUBITAK)
Zitieren
APA
Durak, S., Yetisgin, A. A., Aciksari, A., Ceylan, R., Onder Tokuc, E., Kutlu, O., Karabas, V. L., & Cetinel, S. (2026). Development of Nanoparticle‐Hydrogel Drug Delivery System for Sustained Release of Anti‐VEGF Peptide in Ocular Neovascularization Treatment. Macromolecular Bioscience. https://doi.org/10.1002/mabi.202500263
Vancouver
Durak S, Yetisgin AA, Aciksari A, Ceylan R, Onder Tokuc E, Kutlu O, et al. Development of Nanoparticle‐Hydrogel Drug Delivery System for Sustained Release of Anti‐VEGF Peptide in Ocular Neovascularization Treatment. Macromolecular Bioscience. 2026. doi:10.1002/mabi.202500263
BibTeX
@article{Durak2026,
author = {Durak, Saliha and Yetisgin, Abuzer Alp and Aciksari, Aysegul and Ceylan, Ramazan and Onder Tokuc, Ecem and Kutlu, Ozlem and Karabas, Veysel Levent and Cetinel, Sibel},
title = {Development of Nanoparticle‐Hydrogel Drug Delivery System for Sustained Release of Anti‐VEGF Peptide in Ocular Neovascularization Treatment},
journal = {Macromolecular Bioscience},
year = {2026},
doi = {10.1002/mabi.202500263}
}
EUVIMED